Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRRX2 antisense RNA 1 (PRRX2-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the PRRX2 gene and does not encode a protein[4]. It is classified as an antisense RNA due to its orientation relative to the PRRX2 locus and is implicated in the regulation of gene expression, often through mechanisms such as chromatin remodeling, transcriptional interference, or recruitment of regulatory transcription factors[3][6]. According to expression data, PRRX2-AS1 is highly specific to basal cells of the epidermis and may play a specialized role in skin homeostasis[2]. While antisense lncRNAs in general can regulate tumor-relevant cellular processes (e.g., proliferation, apoptosis) and act as biomarkers for some diseases, there is currently limited direct evidence for PRRX2-AS1’s involvement as a therapeutic target in specific disease contexts or for drug targeting[4][6]. No drugs are currently known to directly target this RNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRRX2 antisense RNA 1 (PRRX2-AS1).